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Notably, thirty-three cases of rotavirus disease with CNS involvement had been reported up until the time when the new rotavirus vaccines were introduced in the United States. 16-22 25-28 Among these 32 cases, less than half (10/24; 42%) of the patients with reported outcomes recovered completely. Five children (21%) died from the disease, whereas the remaining 37% experienced neurological sequelae. 23 With increased awareness evidence has since grown further, and CNS involvement is slowly being recognized as a rare but potentially serious complication in rotavirus gastroenteritis. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Over time, in addition to viral diagnostics radiological features of rotavirus encephalitis are better understood, which may help in directing clinicians to the correct diagnosis. 23 37 During and prior to the time of rotavirus vaccine introduction in different parts of the world, large rotavirus surveillance programs have been instituted. Despite the size and number of such programs, meta-analysis is difficult as very little information can be obtained on rare complications of rotavirus disease. Studies were designed measuring different endpoints and inconsistent criteria and definitions have been applied (if any) for CNS complications. An exception for surveillance studies of seizures in rotavirus disease: A subanalysis of a 5-year rotavirus surveillance in Salt Lake City, Utah (2002-6) is a rare exception specifically focusing of CNS complications. Investigators retrospectively identified 34/59 children with laboratory-confirmed rotavirus infection and >=1 seizure without an alternative medical explanation. They reported one child with cerebral edema on neuroimaging and abnormal EEG and 2 children (7%) who required chronic anticonvulsant therapy concluding "…that seizures associated with rotavirus infection are a relatively benign neurologic condition in young children. With few exceptions, neurodiagnostic studies do not influence management or outcome." 39 .
Precise data and incidence rates with respect to encephalitis/ encephalopathy in large-scale rotavirus surveillance programs are sill lacking. In the meantime, CNS complications have also been reported in gastroenteritis due to other viruses such as norovirus 40 and adenovirus 41 . [58] [59] [60] [61] , attention has also shifted to further understanding the neurologic sequelae and disease burden of congenital CMV disease and non-immunocompromised hosts. In addition, influenza has been increasingly recognized as a vaccine preventable cause of encephalitis, especially in children and adolescents. 67 Initial reports emerged from Japan and the United States [68] [69] [70] [71] [72] [73] [74] [75] and recently, a number of case reports as well as surveillance reports by CDC have been issued on neurologic complications of Influenza A (in particular pandemic H1N1) disease. [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] Example 3: Encephalitis as an adverse event following immunization (AEFI)
Example 2: Encephalitis as a vaccine preventable disease
Encephalitis has not only been described as a viral and/or immunological illness, but also as an adverse event following immunization (AEFI) 89 . The British Pediatric Surveillance Unit conducted a 3-year prospective surveillance aiming to investigate encephalitis as an AEFI in the UK and Ireland 90 By nature, AEFI are rare events requiring large-scale studies, meta-analyses, or extensive (ideally active) surveillance programs to be detected. Reporting bias and awareness are major obstacles to the systematic assessment of AEFI. Resent research revealed that physicians are more likely to report a specific AE if the AE constitutes an event a vaccine in designed to prevent. Interestingly, this "reverse placebo effect" also applied to non-live vaccines. 91 When data have to be pooled from a number of different studies, the use of uniform diagnostic criteria is warranted allowing comparability among studies conducted at different sites. This demand has been met by the Brighton Collaboration, who published a clinical case definition for encephalitis as an AEFI in 2007. 89 The diagnostic criteria for encephalitis as an AEFI are listed in Table 2 , below. The Brighton Collaboration criteria are designed to capture an adverse event independent from any potential triggers, but also to differentiate reliably and consistently between different kinds of CNS involvement, including meningitis, meningo-encephalitis, myleitis, ADEM and the like. The Brighton Collaboration case definitions for aseptic meningitis, encephalitis, myelitis and ADEM have since been evaluated in a retrospective analysis of 255 clinical cases of CNS disease in a Swiss children's hospital. 93 This evaluation study revealed that unless predefined clinical criteria are applied consistently, the demarcation of closely related but distinct CNS disease entities will be missed. ICD-10 coding and diagnoses mentioned in hospital discharge summaries are insufficient and all too often observer-dependent. Encephalitis -Level 3A of diagnostic certainty: 7, 9 (a) Insufficient information is available to distinguish case between acute encephalitis or ADEM; case unable to be definitively classified.
Encephalitis -Exclusion criterion for levels 2 and 3 of diagnostic certainty:
(a) Other diagnosis for illness present. 10 2 If the lowest applicable level of diagnostic certainty of the definition for a definitive category (i.e., Level 3, excluding Level 3A) is met and there is evidence that the criteria of the next higher level of diagnostic certainty (Level 2) are met, the event should be classified in the next category. This approach should be continued until the highest level of diagnostic certainty for a given event can be determined. Thus, if a case fits diagnostic criteria for both categories (encephalitis and ADEM), but reaches a higher level of diagnostic certainty in one, the higher level supercedes, and the case should be classified according to the category in which the higher diagnostic certainty level is reached. TheWorking Group recognizes that under this paradigm, it is possible to reach a higher level of diagnostic certainty forADEMwith less stringent criteria than it is for encephalitis e.g., Level 1 diagnostic certainty for encephalitis requires histopathologic diagnosis, whilst ADEM Level 1 does not require this. However, in the absence of a biological marker, the diagnosis of ADEM rests upon the proper neuroimaging findings in the appropriate clinical context, and the combination of appropriate neuroimaging and a monophasic pattern of illness are as close to a gold standard as exist for this clinical entity. Thus, one may have a higher level of diagnostic certainty of ADEM than of encephalitis, in the absence of other biologic data. When Level 1 ADEM and Level 2 encephalitis, or Level 2 ADEM and Level 3 encephalitis are met, the best category to choose would be ADEM.
Tabe 2. Brighton Collaboration Case Definition for Encephalitis as an AEFI (see www.brightoncollaboration.org)
Assessment of the problem
Most of the attempts to standardize the diagnosis of encephalitis are focusing on adults whereas pediatric studies are facing specific challenges in the differential diagnosis, such as age-dependent symptoms while intellectual capabilities are still developing and the difficulty to distinguish acute neurologic impairment from consequences of perinatal asphyxia and congenital malformations, developmental delay, intoxication and other alternative possible non-infectious causes of encephalopathy. 2, 5 Due to the immaturity of the immune system and the blood-brain barrier, children under the age of two are at a particularly high risk of developing encephalitis during bacterial sepsis or systemic infection with herpesviridae, Tb and many other pathogens. At the same time the chance of recurrence of HSV meningo-encephalitis is difficult to assess and consequences of premature discontinuation of antiviral therapy can be detrimental. [94] [95] [96] [97] [98] [99] Even in older children, the difficulty to identify symptoms of encephalopathy such as behavioral outbursts, decreased responsiveness, and other subtle signs may delay the diagnosis and thus, treatment. 100, 101 In other cases, the differentiation of autoimmune from viral causes of encephalitis causes problems. 100, 4 Without the identification of potential causes of encephalitis, however, the treatment options and prognosis in different types of encephalitis will remain poorly understood. 1, 102 With additional diagnostic and therapeutic options becoming available, and several types of encephalitis vaccine-preventable, the systematic surveillance of encephalitis in children has gained significance, also with respect to everyday clinical care. As indicated above, prospective and retrospective case ascertainment both provide a number of challenges. Prospective surveillance of large cohorts using predefined case definitions is key to avoid inter-rater variability and selection bias. The installment of active surveillance systems in specialized reference centers will ultimately improve the monitoring of encephalitis as an AEFI. Children with acute CNS adverse events are most likely to present in emergency rooms and tertiary care centers rather than private pediatric practices, where the child has usually been immunized. Unless immunizations are systematically captured at the time of investigation, rates of encephalitis and other CNS adverse events following immunization -as opposed to other triggers or causes -can hardly be established. 90, 103 In addition, lumbar puncture is difficult to perform in infants and children, and even if CSF has been obtained, pathogens other than HSV and bacteria are rarely assessed in routine practice. Very little is known for example, about incidence rates of enterovirus infection in pediatric CNS disease. 104 However, effective enterovirus surveillance can also be utilized as a tool for regional polio disease surveillance, as is the case at the German National Reference Laboratory for Enteroviruses at the Robert Koch Institute in Berlin. 105, 106 Hospital-based prospective surveillance systems have been introduced in several locations, including country-wide surveillance systems in the US 4 , France 107 , the UK 2 and Sweden 1 , as well as smaller programs in Taiwan 108 , Crete 109 , and India. 110 Unfortunately, each of these programs use their own case definitions for encephalitis. ".. clinical case definition of acute encephalitis with indication for lumbar puncture, based on the judgment of the patient's attending physician. The clinical case definition of acute encephalitis included new onset of fever (temperature > 38°C) or history of fever during the present illness along with altered mental status, (e.g., confusion, disorientation, coma) and/or a neurological deficit (i.e., focal or diffuse neurological dysfunction or new onset of seizures) with onset of the neurological symptoms within five days prior to hospitalization. Enrollment in the study required that the patient met the clinical case definition and that he or she had cerebrospinal fluid (CSF) pleocytosis (defined as > 4 leukocytes/mm3 for patients > 6 weeks of age and > 14 leukocytes/mm3 for the patients > 6 weeks of age)..."
Huang 102 Long-term cognitive and motor deficits after enterovirus 71 brainstem encephalitis in children Taiwan  Enterovirus  Encephalitis  1998 -2004 "case definition for enterovirus 71 brainstem encephalitis: myoclonus, ataxia, nystagmus, oculomotor palsies, and bulbar palsy, in various combinations, with or without confirmation by neuroimaging".
www.intechopen.com Table 3 . Examples of encephalitis surveillance systems and clinical case definitions used.
Summary and future perspectives
In conclusion, it may be stated that  prospective surveillance systems for encephalitis have been developed in several sites  universal case definitions or inclusion criteria are currently not being applied  clinical encephalitis case definitions are usually not adjusted to age  a large number of prospective studies are laboratory-based with clinical information added after the fact  evidence-based information on the multiple causes of encephalitis only slowly emerging. With the emergence of surveillance systems for encephalitis worldwide, it would be desirable to introduce the use of uniform case definitions and clinical criteria allowing metaanalysis and head-to-head comparisons between studies and sites. As a first step into this direction, a model surveillance system has been introduced in the pediatric emergency rooms at Charité University Medical Center in Berlin in collaboration with the adjacent Robert Koch Institute, as a first cohort to prospectively implement the neurologic case definitions by the Brighton Collaboration while assessing vaccine preventable neurologic disease along with neurologic adverse events following immunization in the same population.
The Charité Meningitis Surveillance at Charité (MenSCh ) Cohort: Prospective Surveillance Systems for CNS inflammation and natural infection.
At Charité, a prospective surveillance system has been put in place monitoring acute presentations of children and adolescents to one of the largest pediatric ERs in Europe. The ERs are located in two different areas of Berlin representing an ethnically diverse population, including up to 40% of children with migratory background (Turkish, Kurdish, Arab/North African, Eastern European). All patients fulfilling predefined case definitions while presenting on regular screening days are automatically enrolled, tested immediately in close collaboration with epidemiologists and the adjacent Robert Koch Institute and followed-up clinically. In the absence of an HMO system in most European countries, this is a powerful method to capture a comprehensive sample of a typical pediatric urban tertiary care population with "naturally occurring infection" and adverse events. Precise immunization histories are taken at the time of presentation. Case-control and other methodology can be used to compensate for lack of randomization. The MenSCh (Meningitis Surveillance at Charité) Cohort is a prospective cohort of children presenting with signs and symptoms of CNS inflammation/infection to the ER. Presentations are classified according to age-adjusted clinical and disease severity scores, but also classified according to standardized case definitions for meningitis, encephalitis, myelitis, ADEM, GBS, seizure and Bell's Palsy by the Brighton Collaboration. Confirmed clinical cases according to the definitions of the Brighton Collaboration, regardless of the trigger (infection, immunization, autoimmune disease), are followed until discharge. Again, detailed immunization histories and laboratory data are captured. After case ascertainment according to standardized case definitions, patients presenting with rare autoimmune AE following immunization will be studied in detail. Vaccines are among the most effective methodologies available to date for the prevention of infectious diseases of childhood. With declining vaccine acceptance in many parts of the world, it will become increasingly important to learn more about the causes of neurologic adverse events in children. It is hoped that the MenSch cohort will provide a useful contribution to the field while monitoring incidences of vaccine preventable disease alongside with adverse events following immunization.
